chqngchang
2021-12-14
[Grin]
sounds good
Pfizer vaccine protecting against hospitalisation during Omicron wave - study<blockquote>辉瑞疫苗可防止奥密克戎浪潮期间住院——研究</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":607921337,"tweetId":"607921337","gmtCreate":1639476799342,"gmtModify":1639476799601,"author":{"id":3582358454168309,"idStr":"3582358454168309","authorId":3582358454168309,"authorIdStr":"3582358454168309","name":"chqngchang","avatar":"https://static.tigerbbs.com/b56233832049ceeac966ba711e0e1f75","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":20,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[Grin] </span>sounds good<br></p></body></html>","htmlText":"<html><head></head><body><p><span>[Grin] </span>sounds good<br></p></body></html>","text":"[Grin] sounds good","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/607921337","repostId":1105025097,"repostType":4,"repost":{"id":"1105025097","kind":"news","pubTimestamp":1639474546,"share":"https://www.laohu8.com/m/news/1105025097?lang=zh_CN&edition=full","pubTime":"2021-12-14 17:35","market":"us","language":"en","title":"Pfizer vaccine protecting against hospitalisation during Omicron wave - study<blockquote>辉瑞疫苗可防止奥密克戎浪潮期间住院——研究</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1105025097","media":"Reuters","summary":"Two doses of Pfizer-BioNTech's COVID-19 vaccine appear to have given 70% protection against hospital","content":"<p>Two doses of Pfizer-BioNTech's COVID-19 vaccine appear to have given 70% protection against hospitalization in South Africa in recent weeks, a major real-world study on the potential impact of Omicron showed on Tuesday, as the country battles a spike in infections linked to the new variant.</p><p><blockquote>周二，一项关于奥密克戎潜在影响的大型现实世界研究显示，最近几周，两剂辉瑞-BioNTech的COVID-19疫苗似乎为南非的住院提供了70%的保护，因为南非正在应对与新变种相关的感染激增。</blockquote></p><p> The study released by South Africa's largest private health insurance administrator, Discovery Health, was based on more than 211,000 positive COVID-19 test results from Nov. 15 to Dec. 7, around 78,000 of which were attributed to Omicron.</p><p><blockquote>这项由南非最大的私人健康保险管理机构Discovery Health发布的研究基于11月15日至12月7日期间超过211,000例阳性COVID-19检测结果，其中约78,000例归因于奥密克戎。</blockquote></p><p> The 78,000 results are not confirmed Omicron cases, meaning the study is not able to draw conclusive findings about the variant labeled \"of concern\" by the World Health Organization.</p><p><blockquote>78,000个结果不是确诊的奥密克戎病例，这意味着该研究无法对世界卫生组织标记为“值得关注”的变种得出结论性发现。</blockquote></p><p> South African scientists have so far confirmed around 550 Omicron sequences, with the variant accounting for 78% of sequences from November, more than the previously dominant Delta variant.</p><p><blockquote>南非科学家迄今已确认约550个奥密克戎病毒序列，该变种占11月序列的78%，超过了此前占主导地位的德尔塔变异毒株病毒。</blockquote></p><p> South Africa alerted the world to Omicron late last month, triggering an alarm that it could cause another surge in global infections, and lead to the imposition of travel restrictions on southern Africa. South Africa's daily infections have since risen to around 20,000 in recent days.</p><p><blockquote>南非上月底向世界发出奥密克戎警报，引发了一场警报，即它可能导致全球感染人数再次激增，并导致对南部非洲实施旅行限制。最近几天，南非的每日感染人数已上升至2万人左右。</blockquote></p><p> Based on analysis by Discovery's clinical research and actuarial teams, and in collaboration with South Africa's Medical Research Council (SAMRC), the real-world study calculated that two doses of Pfizer-BioNTech offered 70% protection against hospitalization during the recent surge in cases and 33% protection against infection.</p><p><blockquote>根据Discovery的临床研究和精算团队的分析，并与南非医学研究委员会(SAMRC)合作，这项真实世界的研究计算出，在最近病例激增期间，两剂辉瑞-BioNTech可提供70%的住院保护和33%的感染保护。</blockquote></p><p> South Africa is using the Pfizer-BioNTech and Johnson & Johnson vaccines in its COVID-19 immunization campaign, with more than 20 million Pfizer doses administered so far.</p><p><blockquote>南非正在其新冠肺炎免疫活动中使用辉瑞-BioNTech和强生疫苗，迄今已接种超过2000万剂辉瑞疫苗。</blockquote></p><p> It concluded that there was a higher risk of reinfection during the fourth wave than during previous waves and that the risk of hospitalization among adults diagnosed with COVID-19 was 29% lower than during the country's first wave early last year.</p><p><blockquote>它的结论是，第四波再次感染的风险比前几波更高，被诊断患有新冠肺炎的成年人住院的风险比去年年初该国第一波低29%。</blockquote></p><p> Children appeared to have a 20% higher risk of hospital admission with complications during the fourth wave than during the first, despite a very low absolute incidence, it said.</p><p><blockquote>报告称，尽管绝对发病率非常低，但第四波儿童因并发症住院的风险似乎比第一波高20%。</blockquote></p><p> Discovery cautioned that the study's findings should be considered preliminary.</p><p><blockquote>Discovery警告说，这项研究的发现应该被认为是初步的。</blockquote></p><p> Glenda Gray, SAMRC president, said it was important that the Pfizer-BioNTech vaccine appeared to be offering good protection against severe disease and hospitalization.</p><p><blockquote>SAMRC主席Glenda Gray表示，重要的是辉瑞-BioNTech疫苗似乎对严重疾病和住院提供了良好的保护。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer vaccine protecting against hospitalisation during Omicron wave - study<blockquote>辉瑞疫苗可防止奥密克戎浪潮期间住院——研究</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer vaccine protecting against hospitalisation during Omicron wave - study<blockquote>辉瑞疫苗可防止奥密克戎浪潮期间住院——研究</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-12-14 17:35</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Two doses of Pfizer-BioNTech's COVID-19 vaccine appear to have given 70% protection against hospitalization in South Africa in recent weeks, a major real-world study on the potential impact of Omicron showed on Tuesday, as the country battles a spike in infections linked to the new variant.</p><p><blockquote>周二，一项关于奥密克戎潜在影响的大型现实世界研究显示，最近几周，两剂辉瑞-BioNTech的COVID-19疫苗似乎为南非的住院提供了70%的保护，因为南非正在应对与新变种相关的感染激增。</blockquote></p><p> The study released by South Africa's largest private health insurance administrator, Discovery Health, was based on more than 211,000 positive COVID-19 test results from Nov. 15 to Dec. 7, around 78,000 of which were attributed to Omicron.</p><p><blockquote>这项由南非最大的私人健康保险管理机构Discovery Health发布的研究基于11月15日至12月7日期间超过211,000例阳性COVID-19检测结果，其中约78,000例归因于奥密克戎。</blockquote></p><p> The 78,000 results are not confirmed Omicron cases, meaning the study is not able to draw conclusive findings about the variant labeled \"of concern\" by the World Health Organization.</p><p><blockquote>78,000个结果不是确诊的奥密克戎病例，这意味着该研究无法对世界卫生组织标记为“值得关注”的变种得出结论性发现。</blockquote></p><p> South African scientists have so far confirmed around 550 Omicron sequences, with the variant accounting for 78% of sequences from November, more than the previously dominant Delta variant.</p><p><blockquote>南非科学家迄今已确认约550个奥密克戎病毒序列，该变种占11月序列的78%，超过了此前占主导地位的德尔塔变异毒株病毒。</blockquote></p><p> South Africa alerted the world to Omicron late last month, triggering an alarm that it could cause another surge in global infections, and lead to the imposition of travel restrictions on southern Africa. South Africa's daily infections have since risen to around 20,000 in recent days.</p><p><blockquote>南非上月底向世界发出奥密克戎警报，引发了一场警报，即它可能导致全球感染人数再次激增，并导致对南部非洲实施旅行限制。最近几天，南非的每日感染人数已上升至2万人左右。</blockquote></p><p> Based on analysis by Discovery's clinical research and actuarial teams, and in collaboration with South Africa's Medical Research Council (SAMRC), the real-world study calculated that two doses of Pfizer-BioNTech offered 70% protection against hospitalization during the recent surge in cases and 33% protection against infection.</p><p><blockquote>根据Discovery的临床研究和精算团队的分析，并与南非医学研究委员会(SAMRC)合作，这项真实世界的研究计算出，在最近病例激增期间，两剂辉瑞-BioNTech可提供70%的住院保护和33%的感染保护。</blockquote></p><p> South Africa is using the Pfizer-BioNTech and Johnson & Johnson vaccines in its COVID-19 immunization campaign, with more than 20 million Pfizer doses administered so far.</p><p><blockquote>南非正在其新冠肺炎免疫活动中使用辉瑞-BioNTech和强生疫苗，迄今已接种超过2000万剂辉瑞疫苗。</blockquote></p><p> It concluded that there was a higher risk of reinfection during the fourth wave than during previous waves and that the risk of hospitalization among adults diagnosed with COVID-19 was 29% lower than during the country's first wave early last year.</p><p><blockquote>它的结论是，第四波再次感染的风险比前几波更高，被诊断患有新冠肺炎的成年人住院的风险比去年年初该国第一波低29%。</blockquote></p><p> Children appeared to have a 20% higher risk of hospital admission with complications during the fourth wave than during the first, despite a very low absolute incidence, it said.</p><p><blockquote>报告称，尽管绝对发病率非常低，但第四波儿童因并发症住院的风险似乎比第一波高20%。</blockquote></p><p> Discovery cautioned that the study's findings should be considered preliminary.</p><p><blockquote>Discovery警告说，这项研究的发现应该被认为是初步的。</blockquote></p><p> Glenda Gray, SAMRC president, said it was important that the Pfizer-BioNTech vaccine appeared to be offering good protection against severe disease and hospitalization.</p><p><blockquote>SAMRC主席Glenda Gray表示，重要的是辉瑞-BioNTech疫苗似乎对严重疾病和住院提供了良好的保护。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/pfizer-vaccine-protecting-against-hospitalisation-090645635.html\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://finance.yahoo.com/news/pfizer-vaccine-protecting-against-hospitalisation-090645635.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105025097","content_text":"Two doses of Pfizer-BioNTech's COVID-19 vaccine appear to have given 70% protection against hospitalization in South Africa in recent weeks, a major real-world study on the potential impact of Omicron showed on Tuesday, as the country battles a spike in infections linked to the new variant.\nThe study released by South Africa's largest private health insurance administrator, Discovery Health, was based on more than 211,000 positive COVID-19 test results from Nov. 15 to Dec. 7, around 78,000 of which were attributed to Omicron.\nThe 78,000 results are not confirmed Omicron cases, meaning the study is not able to draw conclusive findings about the variant labeled \"of concern\" by the World Health Organization.\nSouth African scientists have so far confirmed around 550 Omicron sequences, with the variant accounting for 78% of sequences from November, more than the previously dominant Delta variant.\nSouth Africa alerted the world to Omicron late last month, triggering an alarm that it could cause another surge in global infections, and lead to the imposition of travel restrictions on southern Africa. South Africa's daily infections have since risen to around 20,000 in recent days.\nBased on analysis by Discovery's clinical research and actuarial teams, and in collaboration with South Africa's Medical Research Council (SAMRC), the real-world study calculated that two doses of Pfizer-BioNTech offered 70% protection against hospitalization during the recent surge in cases and 33% protection against infection.\nSouth Africa is using the Pfizer-BioNTech and Johnson & Johnson vaccines in its COVID-19 immunization campaign, with more than 20 million Pfizer doses administered so far.\nIt concluded that there was a higher risk of reinfection during the fourth wave than during previous waves and that the risk of hospitalization among adults diagnosed with COVID-19 was 29% lower than during the country's first wave early last year.\nChildren appeared to have a 20% higher risk of hospital admission with complications during the fourth wave than during the first, despite a very low absolute incidence, it said.\nDiscovery cautioned that the study's findings should be considered preliminary.\nGlenda Gray, SAMRC president, said it was important that the Pfizer-BioNTech vaccine appeared to be offering good protection against severe disease and hospitalization.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":3424,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":16,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/607921337"}
精彩评论